Generic Rezurock Availability
Last updated on Nov 6, 2024.
Rezurock is a brand name of belumosudil, approved by the FDA in the following formulation(s):
REZUROCK (belumosudil mesylate - tablet;oral)
-
Manufacturer: KADMON PHARMS LLC
Approval date: July 16, 2021
Strength(s): EQ 200MG BASE [RLD]
Has a generic version of Rezurock been approved?
No. There is currently no therapeutically equivalent version of Rezurock available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rezurock. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Rho kinase inhibitors
Patent 10,183,931
Issued: January 22, 2019
Inventor(s): Poyurovsky Masha & Kim Ji-In & Liu Kevin & Zanin-Zhorov Alexandra
Assignee(s): Kadmon Corporation, LLCThe invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.
Patent expiration dates:
- October 7, 2033✓
- October 7, 2033
-
Rho kinase inhibitors
Patent 10,696,660
Issued: June 30, 2020
Inventor(s): Poyurovsky Masha V. & Kim Ji-In & Liu Kevin G. & Zanin-Zhorov Alexandra
Assignee(s): Kadmon Corporation, LLCThe invention relates to inhibitors of ROCK1 and/or ROCK2. Also provided are methods of treating diseases and disorders involving inhibiting ROCK1 and/or ROCK2.
Patent expiration dates:
- October 7, 2033✓
- October 7, 2033
-
Patent 11,311,541
Patent expiration dates:
- April 9, 2035✓
- April 9, 2035
-
Patent 12,097,202
Patent expiration dates:
- July 14, 2042✓
- July 14, 2042
-
Pharmacokinetically improved compounds
Patent 8,357,693
Issued: January 22, 2013
Inventor(s): Bartolozzi Alessandra & Campbell Stewart & Foudoulakis Hope & Kirk Brian & Ram Siya & Sweetnam Paul
Assignee(s): Surface Logix, Inc.The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease.
Patent expiration dates:
- October 30, 2029✓✓✓
- October 30, 2029
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 16, 2026 - NEW CHEMICAL ENTITY
- July 16, 2028 - TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY
More about Rezurock (belumosudil)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
